Patrizia Stoitzner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6457606/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early antitumor activity of oral Langerhans cells is compromised by a carcinogen. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	15
2	Targeted delivery of a vaccine protein to Langerhans cells in the human skin via the Câ€ŧype lectin receptor Langerin. European Journal of Immunology, 2022, 52, 1829-1841.	2.9	5
3	Antigen targeting to dendritic cells: Still a place in future immunotherapy?. European Journal of Immunology, 2022, 52, 1909-1924.	2.9	7
4	Notch-Mediated Generation of Monocyte-Derived Langerhans Cells: Phenotype and Function. Journal of Investigative Dermatology, 2021, 141, 84-94.e6.	0.7	10
5	BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes. Cancer Immunology, Immunotherapy, 2021, 70, 1635-1647.	4.2	13
6	CD73 contributes to antiâ€inflammatory properties of afferent lymphatic endothelial cells in humans and mice. European Journal of Immunology, 2021, 51, 231-246.	2.9	12
7	Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants. Oncolmmunology, 2021, 10, 1959140.	4.6	4
8	Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy. , 2021, 9, e000832.		23
9	Laserâ€assisted epicutaneous immunization to target human skin dendritic cells. Experimental Dermatology, 2021, 30, 1279-1289.	2.9	6
10	Specific Protein Antigen Delivery to Human Langerhans Cells in Intact Skin. Frontiers in Immunology, 2021, 12, 732298.	4.8	9
11	E-Cadherin is Dispensable to Maintain Langerhans Cells in the Epidermis. Journal of Investigative Dermatology, 2020, 140, 132-142.e3.	0.7	33
12	A TLR7 agonist strengthens T and NK cell function during BRAFâ€ŧargeted therapy in a preclinical melanoma model. International Journal of Cancer, 2020, 146, 1409-1420.	5.1	22
13	Combining chemotherapy and autologous peptideâ€pulsed dendritic cells provides survival benefit in stageÂIV melanoma patients. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1270-1277.	0.8	2
14	Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity. Molecular Oncology, 2020, 14, 1930-1946.	4.6	21
15	539â€High dimensional analysis of the human lymph node during melanoma progression reveals shifts in myeloid content that relate to differential T cell content. , 2020, , .		0
16	A Specific, Glycomimetic Langerin Ligand for Human Langerhans Cell Targeting. ACS Central Science, 2019, 5, 808-820.	11.3	64
17	A Liposomal Platform for Delivery of a Protein Antigen to Langerin-Expressing Cells. Biochemistry, 2019, 58, 2576-2580.	2.5	15
18	Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment. International Journal of Cancer, 2019. 145. 1958-1969.	5.1	21

#	Article	IF	CITATIONS
19	Langerin+ DCs regulate innate IL-17 production in the oral mucosa during Candida albicans-mediated infection. PLoS Pathogens, 2018, 14, e1007069.	4.7	51
20	Monitoring Skin Dendritic Cells in Steady State and Inflammation by Immunofluorescence Microscopy and Flow Cytometry. Methods in Molecular Biology, 2017, 1559, 37-52.	0.9	8
21	Langerhans cells and NK cells cooperate in the inhibition of chemical skin carcinogenesis. Oncolmmunology, 2017, 6, e1260215.	4.6	26
22	T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. Journal of Hematology and Oncology, 2016, 9, 116.	17.0	201
23	Langerhans cells in the sebaceous gland of the murine skin. Experimental Dermatology, 2015, 24, 899-901.	2.9	2
24	Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses. Frontiers in Immunology, 2015, 6, 534.	4.8	134
25	Impaired gp100-Specific CD8 + T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model. Journal of Investigative Dermatology, 2015, 135, 2785-2793.	0.7	19
26	The Late Endosomal Adaptor Molecule p14 (LAMTOR2) Regulates TGFβ1-Mediated Homeostasis of Langerhans Cells. Journal of Investigative Dermatology, 2015, 135, 119-129.	0.7	24
27	Langerhans Cell Homeostasis and Activation Is Altered in Hyperplastic Human Papillomavirus Type 16 E7 Expressing Epidermis. PLoS ONE, 2015, 10, e0127155.	2.5	20
28	Human skin dendritic cells can be targeted in situ by intradermal injection of antibodies against lectin receptors. Experimental Dermatology, 2014, 23, 909-915.	2.9	26
29	LAMTOR2 regulates dendritic cell homeostasis through FLT3-dependent mTOR signalling. Nature Communications, 2014, 5, 5138.	12.8	38
30	Anatomical distribution analysis reveals lack of Langerin+ dermal dendritic cells in footpads and tail of C57 <scp>BL</scp> /6 mice. Experimental Dermatology, 2014, 23, 354-356.	2.9	5
31	NK Cells Are Required for Dendritic Cell–Based Immunotherapy at the Time of Tumor Challenge. Journal of Immunology, 2014, 192, 2514-2521.	0.8	43
32	Murine Langerin ⁺ dermal dendritic cells prime <scp>CD</scp> 8 ⁺ <scp>T</scp> cells while <scp>L</scp> angerhans cells induce crossâ€ŧolerance. EMBO Molecular Medicine, 2014, 6, 1191-1204.	6.9	76
33	The late endosomal adaptor molecule p14 (LAMTOR2) represents a novel regulator of Langerhans cell homeostasis. Blood, 2014, 123, 217-227.	1.4	48
34	Lapatinib and doxorubicin enhance the <scp>S</scp> tat1â€dependent antitumor immune response. European Journal of Immunology, 2013, 43, 2718-2729.	2.9	108
35	The Role of the E3 Ligase Cbl-B in Murine Dendritic Cells. PLoS ONE, 2013, 8, e65178.	2.5	14
36	Skin Langerin+ Dendritic Cells Transport Intradermally Injected Anti–DEC-205 Antibodies but Are Not Essential for Subsequent Cytotoxic CD8+ T Cell Responses. Journal of Immunology, 2012, 188, 2146-2155.	0.8	27

#	Article	IF	CITATIONS
37	Reinforcement of cancer immunotherapy by adoptive transfer of <i>cblb</i> â€deficient CD8 ⁺ T cells combined with a DC vaccine. Immunology and Cell Biology, 2012, 90, 130-134.	2.3	22
38	Expression of XCR1 Characterizes the Batf3-Dependent Lineage of Dendritic Cells Capable of Antigen Cross-Presentation. Frontiers in Immunology, 2012, 3, 214.	4.8	198
39	Langerhans Cells Come in Waves. Immunity, 2012, 37, 766-768.	14.3	5
40	Cytip regulates dendriticâ€cell function in contact hypersensitivity. European Journal of Immunology, 2012, 42, 589-597.	2.9	7
41	Different role of CD73 in leukocyte trafficking via blood and lymph vessels. Blood, 2011, 117, 4387-4393.	1.4	62
42	Langerin, the "Catcher in the Rye†An important receptor for pathogens on Langerhans cells. European Journal of Immunology, 2011, 41, 2526-2529.	2.9	18
43	ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8+ T Cells. Journal of Immunology, 2011, 187, 55-63.	0.8	105
44	Murine Melanoma-Infiltrating Dendritic Cells Are Defective in Antigen Presenting Function Regardless of the Presence of CD4+CD25+ Regulatory T Cells. PLoS ONE, 2011, 6, e17515.	2.5	34
45	Conditioning of the Injection Site With CpG Enhances the Migration of Adoptively Transferred Dendritic Cells and Endogenous CD8+ T-cell Responses. Journal of Immunotherapy, 2010, 33, 115-125.	2.4	15
46	Langerhans cells as targets for immunotherapy against skin cancer. Immunology and Cell Biology, 2010, 88, 431-437.	2.3	45
47	The Langerhans cell controversy: are they immunostimulatory or immunoregulatory cells of the skin immune system?. Immunology and Cell Biology, 2010, 88, 348-350.	2.3	18
48	Langerhans cells and more: langerinâ€expressing dendritic cell subsets in the skin. Immunological Reviews, 2010, 234, 120-141.	6.0	372
49	Epidermal Langerhans Cells Rapidly Capture and Present Antigens from C-Type Lectin-Targeting Antibodies Deposited in the Dermis. Journal of Investigative Dermatology, 2010, 130, 755-762.	0.7	94
50	Functional Redundancy of Langerhans Cells and Langerin+ Dermal Dendritic Cells in Contact Hypersensitivity. Journal of Investigative Dermatology, 2010, 130, 2752-2759.	0.7	98
51	Isolation of Skin Dendritic Cells from Mouse and Man. Methods in Molecular Biology, 2010, 595, 235-248.	0.9	34
52	Langerhans cells and dermal dendritic cells capture protein antigens in the skin: Possible targets for vaccination through the skin. Immunobiology, 2010, 215, 770-779.	1.9	46
53	Targeting Antigen to MHC Class II Molecules Promotes Efficient Cross-Presentation and Enhances Immunotherapy. Journal of Immunology, 2009, 182, 1260-1269.	0.8	37
54	Glycolipids Injected into the Skin Are Presented to NKT Cells in the Draining Lymph Node Independently of Migratory Skin Dendritic Cells. Journal of Immunology, 2009, 182, 7644-7654.	0.8	16

#	Article	IF	CITATIONS
55	Langerin+CD8α+ Dendritic Cells Are Critical for Cross-Priming and IL-12 Production in Response to Systemic Antigens. Journal of Immunology, 2009, 183, 7732-7742.	0.8	84
56	Skin Inflammation Is Not Sufficient to Break Tolerance Induced against a Novel Antigen. Journal of Immunology, 2009, 183, 1133-1143.	0.8	19
57	Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy. Cancer Immunology, Immunotherapy, 2009, 58, 1137-1147.	4.2	42
58	Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunology, Immunotherapy, 2008, 57, 1665-1673.	4.2	77
59	Expression of Langerin/CD207 reveals dendritic cell heterogeneity between inbred mouse strains. Immunology, 2008, 123, 339-347.	4.4	48
60	The lymph vessel network in mouse skin visualised with antibodies against the hyaluronan receptor LYVE-1. Immunobiology, 2008, 213, 715-728.	1.9	18
61	Tumor Immunotherapy by Epicutaneous Immunization Requires Langerhans Cells. Journal of Immunology, 2008, 180, 1991-1998.	0.8	88
62	Peroxisome Proliferator-Activated Receptor-α Activation Inhibits Langerhans Cell Function. Journal of Immunology, 2007, 178, 4362-4372.	0.8	39
63	Trafficking of Dendritic Cells. , 2006, , 184-215.		1
64			
	Viewpoint 3. Experimental Dermatology, 2006, 15, 921-922.	2.9	0
65	Epidermal Langerhans cellsâ€"Changing views on their function in vivo. Immunology Letters, 2006, 106, 119-125.	2.9 2.5	0 74
65 66	 Viewpoint 3. Experimental Dermatology, 2006, 15, 921-922. Epidermal Langerhans cellsâ€"Changing views on their function in vivo. Immunology Letters, 2006, 106, 119-125. The dermal microenvironment induces the expression of the alternative activation marker CD301/mMGL in mononuclear phagocytes, independent of IL-4/IL-13 signaling. Journal of Leukocyte Biology, 2006, 80, 838-849. 	2.9 2.5 3.3	0 74 57
65 66 67	 Viewpoint 3. Experimental Dermatology, 2006, 15, 921-922. Epidermal Langerhans cellsâ€"Changing views on their function in vivo. Immunology Letters, 2006, 106, 119-125. The dermal microenvironment induces the expression of the alternative activation marker CD301/mMGL in mononuclear phagocytes, independent of IL-4/IL-13 signaling. Journal of Leukocyte Biology, 2006, 80, 838-849. Langerhans cells cross-present antigen derived from skin. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7783-7788. 	2.9 2.5 3.3 7.1	0 74 57 180
65 66 67 68	 Viewpoint 3. Experimental Dermatology, 2006, 15, 921-922. Epidermal Langerhans cellsâ€"Changing views on their function in vivo. Immunology Letters, 2006, 106, 119-125. The dermal microenvironment induces the expression of the alternative activation marker CD301/mMGL in mononuclear phagocytes, independent of IL-4/IL-13 signaling. Journal of Leukocyte Biology, 2006, 80, 838-849. Langerhans cells cross-present antigen derived from skin. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7783-7788. Development and maturation of Langerhans cells, spleen and bone marrow dendritic cells in TNF-î±/lymphotoxin-î± double-deficient mice. Immunology Letters, 2005, 96, 109-120. 	2.9 2.5 3.3 7.1 2.5	0 74 57 180 0
 65 66 67 68 69 	 Viewpoint 3. Experimental Dermatology, 2006, 15, 921-922. Epidermal Langerhans cellsâ€"Changing views on their function in vivo. Immunology Letters, 2006, 106, 119-125. The dermal microenvironment induces the expression of the alternative activation marker CD301/mMGL in mononuclear phagocytes, independent of IL-4/IL-13 signaling. Journal of Leukocyte Biology, 2006, 80, 838-849. Langerhans cells cross-present antigen derived from skin. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7783-7788. Development and maturation of Langerhans cells, spleen and bone marrow dendritic cells in TNF-α/lymphotoxin-α double-deficient mice. Immunology Letters, 2005, 96, 109-120. Migratory Langerhans Cells in Mouse Lymph Nodes in Steady State and Inflammation. Journal of Investigative Dermatology, 2005, 125, 116-125. 	2.9 2.5 3.3 7.1 2.5 0.7	0 74 57 180 0 79
 65 66 67 68 69 70 	 Viewpoint 3. Experimental Dermatology, 2006, 15, 921-922. Epidermal Langerhans cellsâ€"Changing views on their function in vivo. Immunology Letters, 2006, 106, 119-125. The dermal microenvironment induces the expression of the alternative activation marker CD301/mMGL in mononuclear phagocytes, independent of iL-4/IL-13 signaling. Journal of Leukocyte Biology, 2006, 80, 838-849. Langerhans cells cross-present antigen derived from skin. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7783-7788. Development and maturation of Langerhans cells, spleen and bone marrow dendritic cells in TNF-1±/lymphotoxin-1± double-deficient mice. Immunology Letters, 2005, 96, 109-120. Migratory Langerhans Cells in Mouse Lymph Nodes in Steady State and Inflammation. Journal of Investigative Dermatology, 2005, 125, 116-125. Mouse Lymphoid Tissue Contains Distinct Subsets of Langerin/CD207+ Dendritic Cells, Only One of Which Represents Epidermal-Derived Langerhans Cells. Journal of Investigative Dermatology, 2005, 125, 983-994. 	2.9 2.5 3.3 7.1 2.5 0.7 0.7	0 74 57 180 0 79 87
 65 66 67 68 69 70 71 	 Viewpoint 3. Experimental Dermatology, 2006, 15, 921-922. Epidermal Langerhans cellsâ€"Changing views on their function in vivo. Immunology Letters, 2006, 106, 119-125. The dermal microenvironment induces the expression of the alternative activation marker CD301/mMGL in mononuclear phagocytes, independent of IL-4/IL-13 signaling. Journal of Leukocyte Biology, 2006, 80, 838-849. Langerhans cells cross-present antigen derived from skin. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7783-7788. Development and maturation of Langerhans cells, spleen and bone marrow dendritic cells in TNF-I±/lymphotoxin-I± double-deficient mice. Immunology Letters, 2005, 96, 109-120. Migratory Langerhans Cells in Mouse Lymph Nodes in Steady State and Inflammation. Journal of Investigative Dermatology, 2005, 125, 116-125. Mouse Lymphoid Tissue Contains Distinct Subsets of Langerin/CD207+ Dendritic Cells, Only One of Which Represents Epidermal-Derived Langerhans Cells. Journal of Investigative Dermatology, 2005, 125, 983-994. Langerhans cells are strongly reduced in the skin of transgenic mice overexpressing follistatin in the epidermis. European Journal of Cell Biology, 2005, 84, 733-741. 	2.9 2.5 3.3 7.1 2.5 0.7 0.7 3.6	0 74 57 180 0 79 87 23

#	Article	IF	CITATIONS
73	IL-4 supports the generation of a dendritic cell subset from murine bone marrow with altered endocytosis capacity. Journal of Leukocyte Biology, 2005, 77, 535-543.	3.3	40
74	Expression of Câ€ŧype lectin receptors by subsets of dendritic cells in human skin. International Immunology, 2004, 16, 877-887.	4.0	114
75	Ontogeny of Langerin/CD207 Expression in the Epidermis of Mice. Journal of Investigative Dermatology, 2004, 122, 670-672.	0.7	55
76	A Model System Using Tape Stripping for Characterization of Langerhans Cell-Precursors In Vivo. Journal of Investigative Dermatology, 2004, 122, 1165-1174.	0.7	71
77	Macrophages and Dendritic Cells Constitute a Major Subpopulation of Cells in the Mouse Dermis. Journal of Investigative Dermatology, 2004, 123, 876-879.	0.7	100
78	Langerhans cells - dendritic cells of the epidermis. Apmis, 2003, 111, 725-740.	2.0	210
79	Visualization and Characterization of Migratory Langerhans Cells in Murine Skin and Lymph Nodes by Antibodies Against Langerin/CD207. Journal of Investigative Dermatology, 2003, 120, 266-274.	0.7	155
80	Adenosine Slows Migration of Dendritic Cells but Does Not Affect Other Aspects of Dendritic Cell Maturation. Journal of Investigative Dermatology, 2003, 121, 300-307.	0.7	42
81	ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood, 2003, 102, 613-620.	1.4	118
82	Matrix Metalloproteinases 9 and 2 Are Necessary for the Migration of Langerhans Cells and Dermal Dendritic Cells from Human and Murine Skin. Journal of Immunology, 2002, 168, 4361-4371.	0.8	252
83	A Close-Up View of Migrating Langerhans Cells in the Skin. Journal of Investigative Dermatology, 2002, 118, 117-125.	0.7	127
84	Migration of dendritic cells into lymphatics—The langerhans cell example: Routes, regulation, and relevance. International Review of Cytology, 2001, 207, 237-270.	6.2	77
85	Interleukin-16 Supports the Migration of Langerhans Cells, Partly in a CD4-Independent Way. Journal of Investigative Dermatology, 2001, 116, 641-649.	0.7	33
86	Migration of Langerhans cells and dermal dendritic cells in skin organ cultures: augmentation by TNF-α and IL-1 β. Journal of Leukocyte Biology, 1999, 66, 462-470.	3.3	110
87	Entry Into Afferent Lymphatics and Maturation In Situ of Migrating Murine Cutaneous Dendritic Cells. Journal of Investigative Dermatology, 1998, 110, 441-448.	0.7	104